Objective
The PREFER project will deliver an overview and evaluation of preference elicitation methods to be applied in the entire drug life cycle, i.e. in the early stages of identifying medical needs, in clinical testing, to guide decisions on reimbursement and to make decisions on withdrawal of drugs from the market. A broad array of (combinations of) patient preference methods will be tested prospectively in a large number of case studies. The availability of large patient cohorts will enable to test new methods or deviations from existing methods in a randomized manner, by comparing well-known methods with newer ones. The use of simulation studies will both contribute to smarter design of case studies and to exploring the sensitivity of outcomes of preference studies. Based on discussions with a broad representation of stakeholders e.g. patients, patient organisations, regulatory authorities, HTA bodies and reimbursement agencies, suitable methods will be tested and their contributions to improved decision making will be discussed in recommendations adapted to the needs of all relevant stakeholders. The recommendations from PREFER are expected to lead to changed practices, in that industry will routinely assess whether a preference study would add value at key decision points in the medicinal product life cycle and, if so, implement patient-preference elicitation studies according to the PREFER project recommendations. The PREFER consortium consist of 16 industry partners and 16 academic and SME members including representation from academia, patient organizations, HTA bodies, reimbursement agencies, and project management.
Fields of science
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
751 05 Uppsala
Sweden
See on map
Participants (35)
3584 CX Utrecht
See on map
3062 PA Rotterdam
See on map
3000 Leuven
See on map
B15 2TT Birmingham
See on map
91054 Erlangen
See on map
20121 Milano
See on map
2330 MERKSPLAS
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
2330 MERKSPLAS
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
70126 BARI
See on map
1210 Bruxelles / Brussel
See on map
81677 MUNCHEN
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
NE1 7RU Newcastle Upon Tyne
See on map
1000 Bruxelles / Brussel
See on map
SE1 0BU London
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
4056 Basel
See on map
CB4 0WD Cambridge
See on map
2333 BE Leiden
See on map
Participation ended
13353 Berlin
See on map
RG21 4FA Basingstoke
See on map
2340 Beerse
See on map
94250 GENTILLY
See on map
4123 Allschwil
See on map
CT13 9NJ Sandwich
See on map
08889 Whitehouse Station Nj
See on map
151 85 Sodertaelje
See on map
35041 MARBURG
See on map
64293 Darmstadt
See on map
4070 Basel
See on map
SL6 4XE Maidenhead
See on map
Participation ended
WC2B 4AE London
See on map
BRUSSELS Brussels / Bruxelles
See on map
N1 6AH LONDON
See on map
Participation ended
3015 GD Rotterdam
See on map
51373 Leverkusen
See on map
8152 Glattpark
See on map